Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human papillomavirus 9-valent vaccine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant human papillomavirus 9-valent vaccine is a non-infectious, recombinant vaccine designed to protect against nine types of human papillomavirus (HPV): types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The vaccine is composed of purified virus-like particles (VLPs) formed from the major capsid protein L1 of each HPV type. These VLPs are produced using recombinant Saccharomyces cerevisiae yeast cells and self-assemble to mimic the structure of natural HPV virions without containing viral DNA or causing infection[8][6]. The primary mechanism involves stimulating the immune system to produce neutralizing antibodies that prevent initial infection by binding to the virus and blocking its entry into host cells[1][7]. Gardasil 9 is indicated for prevention of cervical, vulvar, vaginal and anal cancers; cervical adenocarcinoma; precancerous or dysplastic lesions; and genital warts caused by these nine HPV types[6][7]. The developer and manufacturer is Merck Sharp & Dohme LLC.
- Brand names
- Gardasil 9Gardasil9Gardasil-9
- Other names
- Papillomavirus (9-Valent) Vaccine (Human, Recombinant)Human Papillomavirus 9-valent Vaccine, Recombinant
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on recombinant human papillomavirus 9-valent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human papillomavirus 9-valent vaccine.